Skip directly to content

Biopharmaceutical Business

Our biopharmaceutical business is divided into four Business Units, each of which broadly work in different areas of medicine. These Business Units are Primary Care, Specialty Care, Oncology and Established Products.

Each Business Unit works with the regulators, the NHS and healthcare professionals, such as GPs, specialists, nurses and pharmacists, to help get our medicines to the patients who need them. Every day, our medicines and vaccines are taken by around 2.7 million people.

The work of these Business Unit teams actually starts right back in the lab. Business Unit colleagues work with our R&D teams to take compounds that we have discovered and have shown “proof of concept” and develop these into licensed medicines, with proven safety and efficacy, so that they can be used by healthcare professionals to help treat patients. 

Through our Established Products Business Unit, we continue to support the medicines in our portfolio even after they are no longer patent protected, to ensure that the NHS and patients can continue to benefit from them for years to come.

Globally, Pfizer has announced plans to internally separate its commercial operations into three business in 2014. These will be the Innovative Pharmaceutical Business, the Vaccines, Oncology and Consumer Healthcare Business, and the Established Pharmaceutical Business.

» Read more about our Biopharmaceutical Business